Hyaluronidase at ANVISA: Registration, Compounding, Buying

Hyaluronidase is the enzyme that breaks down hyaluronic acid and, for that reason, is the main resource in a vascular occlusion, a nodule or an excess of filler with that material. Having the vial in the practice is not in question. What raises doubts is the regulatory side: does the product have a registration? Can it be compounded? Is use in aesthetics on the label? Where to buy without running a health and legal risk?

This guide answers those questions at a review level. It does not cover storage, expiry and kit setup, which are in hyaluronidase in the practice. It also does not include doses, dilutions or injection protocols. And a warning from the start: the status of registrations and rules changes, so checking directly with ANVISA on the day of purchase is worth more than any published list.

What does it mean to be registered with ANVISA?

In Brazil, manufactured drugs can only be sold after being registered with ANVISA. The registration approves a specific product, from a specific manufacturer, with indications, route of administration, dosing and precautions described on the label. It has a term and can be renewed, amended, canceled or lapse.

Three practical points follow:

• Registration is per product, not per substance. Saying "hyaluronidase is registered" is not enough. What matters is whether that vial, from that manufacturer, has a valid registration today.
• Registration describes indications. Using the product outside what is on the label is possible in clinical practice, but it is off-label use, with the responsibility on whoever prescribes it.
• The status can change. A product that was registered a few years ago may have an expired or canceled registration. That is why the check happens at the time of purchase.

The step-by-step for looking up an injectable by name or number is in how to look up an injectable's registration with ANVISA. The search is public and free, on the ANVISA search portal.

Is there a hyaluronidase registered in Brazil?

There is an animal-derived hyaluronidase registered as a drug in the country, with label indications that do not include reversing fillers. Labels for this type of product usually cite uses such as helping the absorption and dispersion of other injected drugs and aiding the reabsorption of extravasated fluids. The status of each registration should be checked at ANVISA itself, because outdated information circulates in courses and websites and may not reflect the current status.

That is why, in HOF, using hyaluronidase to break down hyaluronic acid in a vascular occlusion, a nodule or an unwanted filler is usually described as off-label. That does not make the use prohibited or any less important: complication management guidelines treat the enzyme as a central piece. But it changes what you need to document.

Compounded hyaluronidase: what does the rule say?

Compounding pharmacies follow ANVISA RDC No. 67/2007, which sets out good practices for compounding magistral and officinal preparations for human use in pharmacies. Two points of this rule matter directly to anyone buying hyaluronidase:

• A magistral preparation starts with a prescription. The rule defines a magistral preparation as one made at the pharmacy from the prescription of a qualified professional, intended for an individual patient, with composition, dosage form, dosing and directions for use detailed.
• Sterile products are a separate group. Compounding sterile products, such as injectables, has its own requirements in the rule, with facility, process and quality control demands stricter than those for other preparations. Not every compounding pharmacy is authorized to do it.

The rule provides for exceptional situations and specific rules on stock, and how each case is interpreted depends on health surveillance and on how the pharmacy is classified. ANVISA has also started reviewing the rules for compounding sterile products, so it is worth following the changes. What does not change is the logic: a compounded injectable must come from a pharmacy licensed for sterile products, with compatible lot traceability and quality control.

Manufactured or compounded: how to compare?

The table summarizes what usually differentiates the possible sources. It does not replace checking the actual product in your hands.

In practice, the choice between manufactured and compounded usually comes down to availability, cost and trust in the supplier. Whichever you choose, the minimum criterion is the same: legitimate origin, a traceable lot and the ability to prove all of that if a complication occurs.

How to buy hyaluronidase safely?

A few precautions greatly reduce the risk of having a vial in the practice that is no good just when you need it most:

1. Check the registration or license before paying. Manufactured: registration number and current status. Compounded: the pharmacy's health license for sterile products.
2. Buy from a regulated supplier, with an invoice in the name of the establishment or the professional. Marketplaces, informal resellers and "imported without invoice" are out.
3. Be wary of a price far below market and of vials without a leaflet, without a Portuguese label or without a lot number.
4. Require clear potency and expiry information on the label. The enzyme's activity is expressed in its own units, which cannot be compared between products, just as with the toxin unit.
5. Record on arrival: product, supplier, lot number, expiry and date received.
6. Keep the documentation for the period required for the patient record.

Why does documentation weigh so much?

Hyaluronidase almost always comes into play at a tense moment: an occlusion in the lip, a filler the patient wants undone, a nodule that bothers them. If the case goes badly or turns into a dispute, the first question will be about the product: what it was, where it came from, whether it was within its expiry, whether it was legitimate.

The patient record should contain, for each use:

• clinical indication and time;
• product, manufacturer or pharmacy, lot number and expiry;
• amount used and areas treated, without details that would only belong in an internal protocol;
• information given to the patient, including that it is off-label use, when applicable;
• progress and follow-ups.

The filler's informed consent should mention that hyaluronidase may be needed to treat complications, and that it can also cause reactions. In elective use, such as undoing an old filler, specific consent becomes even more important. The general organization of these records is in patient record and documentation in HOF.

Serious adverse events with drugs can be reported to ANVISA through the official reporting system. This feeds health surveillance and shows the professional's good faith.

How to explain it to the patient?

The patient who researches hyaluronidase usually finds two opposing messages: "it is the antidote to filler" and "it causes severe allergy." The honest conversation lies in the middle.

It also helps to make clear that the enzyme does not act on other materials. If the patient has already received a biostimulator or a permanent product in the area, hyaluronidase does not undo that material.

And in Harmy?

Hyaluronidase regulatory checklist

1. Manufactured product with valid registration checked at ANVISA on the purchase date, or a pharmacy licensed for sterile products.
2. Invoice from a regulated supplier filed.
3. Lot number, expiry and potency recorded on receipt.
4. Off-label use explained to the patient and documented.
5. Filler consent mentioning hyaluronidase and its risks.
6. Allergic reaction protocol in the practice.
7. Each use documented with product, lot number, time and progress.
8. Periodic review of ANVISA and council rules.